ロード中...
HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer
Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most patients eventually develop castration-resistant CaP (CRPC) for which highly effective therapies are limited. We explored the efficacy of a novel agent, HE3235, in inhibiting growth of CRPC in...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Neoplasia Press Inc.
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2767223/ https://ncbi.nlm.nih.gov/pubmed/19881957 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|